Investor Relations Corporate Profile Evolus is a medical aesthetics company focused on providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. FINANCIAL NEWS March 21, 2019 Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau™ in Dermatologic Surgery March 18, 2019 Evolus Reports Fourth Quarter and Full Year 2018 Results March 18, 2019 Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC View all EVENTS Evolus Investor & Analyst Day May 8, 2019 at 9:00 AM EDT Q4 and Full Year 2018 Evolus Earnings Conference Call Mar 18, 2019 at 4:30 PM EDT Call to Discuss Jeuveau™ FDA Approval Feb 4, 2019 at 8:00 AM EST View all PRESENTATION Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies Mar 21, 2019 March 2019 Investor Presentation Mar 18, 2019 Jeuveau™ FDA Approval Presentation Feb 04, 2019
March 21, 2019 Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau™ in Dermatologic Surgery
Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies Mar 21, 2019
